CardioBreathApp vs IMT in Heart Failure - Trial NCT06139653

Timeline & Enrollment

Primary Outcome

Cardiovascular autonomic control by heart rate variability(HRV)

Summary

Heart failure (HF) is a systemic clinical syndrome defined as cardiac dysfunction, which
 causes inadequate blood supply to meet metabolic needs. One of the most expressive markers of
 HF is neurologic exacerbation, with expected sympathetic hyperactivation, increased activity
 of the renin-angiotensin-aldosterone system and elevation of vasopressin levels. These
 changes compensate the low cardiac output in the onset of ventricular dysfunction ensure a
 long term high blood perfusion pressure,though aggravate this dysfunction and contributes to
 the HF progression. There are evidences ofthe therapeutic effects of respiratory exercise
 techniques for HF patients. However, it demands new data for larger prescription and
 employment of these kind of exercises. Advanced technologies allowed the elaboration of the
 application for slow breathing CardioBreath. So far, it requires the possibility of
 comparison of their effects versus widely validated Inspiratory Muscle Trainig (IMT) on
 respiratory and cardiovascular outcomes in order to elucidate their specific benefits. In
 this way compare CardioBreath ® App versus IMT through a crossover randomized clinical trial
 design may elucidate the response effects of these interventions in these patients.

ICD-10 Classifications